

MOON JOHN C
Form 3/A
April 14, 2003

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden
hours per response. . .0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of
the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment
Company Act of 1940

Filed By
Romeo and Dye's
Section 16 Filer
www.section16.net

1. Name and Address of Reporting Person* Moon John C.		2. Date of Event Requiring Statement Month/Day/Year November 18, 2002		4. Issuer Name and Ticker or Trading Symbol Baxter International Inc. BAX	
(Last) (First) (Middle) Baxter International Inc.		3. I.R.S. Identification Number of Reporting Person, if an entity (voluntary)		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below)	
One Baxter Parkway (Street) Deerfield, IL 60015				Corporate Vice President	
(City) (State) (Zip)		Table I Non-Derivative Securities Beneficially Owned			
1. Title of Security (Instr. 4)		2. Amount of Securities Beneficially Owned (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	
4. Nature of Indirect Beneficial Ownership (Instr. 5)					
Common Stock, \$1 par value		34,732		D	
Common Stock, \$1 par value		2,764.6		I	
				By 401(k) Plan	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number

**FORM 3 (continued) Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/ Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or			

Edgar Filing: MOON JOHN C - Form 3/A

				Number of Shares			
Employee Stock Option Plan (Right to Buy)	02.16.01	02.15.08	Common Stock \$1 par value	4,808	\$26.8782	D	
Employee Stock Option Plan (Right to Buy)	11.16.01	11.14.08	Common Stock \$1 par value	10,452	\$29.2102	D	
Employee Stock Option Plan (Right to Buy)	11.15.02	11.13.09	Common Stock \$1 par value	10,452	\$31.4525	D	
Employee Stock Option Plan (Right to Buy)	11.13.03	11.12.10	Common Stock \$1 par value	42,900	\$41.3438	D	
Employee Stock Option Plan (Right to Buy)	11.13.03	11.12.10	Common Stock \$1 par value	4,900	\$41.3438	D	
Employee Stock Option Plan (Right to Buy)	12.31.01	11.12.10	Common Stock \$1 par value	17,500	\$41.3438	D	
Employee Stock Option Plan (Right to Buy)	11.26.04	11.25.11	Common Stock \$1 par value	51,480	\$49.54	D	
Employee Stock Option Plan (Right to Buy)	11.17.05	11.16.12	Common Stock \$1 par value	36,000	\$30.06	D	
Deferred Compensation Plan - Baxter Stock Fund ⁽¹⁾	⁽²⁾	⁽²⁾	Common Stock \$1 par value ⁽¹⁾	441.3 ⁽³⁾	1-for-1	D	

Explanation of Responses:

(1) Reporting person allocated compensation deferred under Baxter's Deferred Compensation Plan ("Plan") to the Baxter Common Stock Fund notional investment alternative. The value of the reporting person's Plan account is based on the performance of the Baxter Common Stock fund and any other benchmark investment funds selected by the reporting person. Amounts deferred are not actually invested in the Baxter Common Stock Fund or Baxter common stock.

(2) Reporting person's account balance under the Plan is payable in cash after termination of employment or on a future date designated in advance by the reporting person, subject to the terms of the Plan. The reporting person may change investment elections quarterly.

(3) Equal to the reporting person's Baxter Common Stock Fund account balance as of November 18, 2002 divided by the \$30.25 which was the closing price of Baxter Common Stock as reported on the New York Stock Exchange on November 18, 2002.

By: /s/ **William M. Link, Attorney-in-Fact**
for John C. Moon

April 14, 2003
Date

**Signature of Reporting Person

**Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed.
If space is insufficient, See Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of
Reed, Thomas J. Sabatino, Jr. and William M. Link, signing singly, the undersigned's true and law
in-fact to:

Edgar Filing: MOON JOHN C - Form 3/A

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Baxter International Inc., Baxter Healthcare Corporation or Baxter World Trade Corporation (collectively "Baxter") Forms 3, 4, 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder and Form 144 under Rule 144 under the Securities Act of 1933;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, 5, or 144 and complete and execute any amendment or amendments thereto, and timely file any such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required of the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, may or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the direction of the undersigned, are not assuming, nor is Baxter assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 and Rule 144 of the Securities Act of 1933.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer an officer and/or director of Baxter International Inc., Baxter Healthcare Corporation or Baxter World Trade Corporation Forms 3, 4, 5 and 144 with respect to the undersigned's holdings of and transactions in securities of Baxter International Inc., Baxter Healthcare Corporation or Baxter World Trade Corporation unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

Edgar Filing: MOON JOHN C - Form 3/A

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 18 day of November, 2002.

/s/ John C. Moon